Roles
- Professor
-
Biography
Secondary School: Phillips Academy Andover
Undergraduate: Washington University, St. Louis. Mo., B.A. 1970
Graduate: Trinity University, San Antonio, Tx. (while in the military), Masters of Science in Microbiology, 1973
Medical School: University of Texas Medical Branch, Galveston, Tx., MD, 1977
Pediatric Residency: University of Minnesota, 1977-1980
Fellowship in Pediatric Infectious Diseases, University of Minnesota, 1980-1983.
Research Fellowship at the National Institutes of Health, Office of Biologics Research and Review, 1983-1986
Faculty, University of Miami Miller School of Medicine, Division of Pediatric Infectious Diseases, 1986-present. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
1. Pediatric HIV/AIDs
2. Childhood Tuberculosis
3.Various topics in Pediatric Infectious Diseases
4. History of Global Pandemics including Smallpox, Plague, HIV/AIDs, and COVID -
Research Interests
1. Pediatric HIV/AIDs
2. Childhood Tuberculosis
3. Congenital toxoplasmosis
4. Pediatric COVID. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 6 clinical trials.
-
Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents
- Principal Investigator: Charles Mitchell
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
Oral FDCs or single tablet regimens have greatly advanced HIV treatment by allowing simplification of dosing and reducing pill burden. However, durable adherence to therapy is essential to achieve viral suppression and prevent emergence of resistancemutations. Among regimens of comparable efficacy, physicians and PWH who receive ART rate total pill burden, dosing frequency, and safety concerns among the greatest obstacles to achieving and sustaining high adherence. A LA injectable may provide analternative treatment option for PWH who are unable to achieve suppression on oral ART. CAB LA + RPV LA comprises long-acting injectable formulations of the potent integrase inhibitor CAB and the diarylpyrimidine derivative and potent NNRTI, RPV. CAB LA + RPV LA is currently approved in the US (as CABENUVA) as a completeregimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg and for adults in EU and UK (as VOCABRIA + REKAMBYS) to replace the current ARV regimen in those who are virologicallysuppressed (HIV-1 RNA <50 c/mL) on a stable ARV regimen with no history of treatment failure and with no known or suspected resistance to either CAB or RPV. The proposed study 221611 aims to demonstrate superiority of CAB LA + RPV LA compared to oral ART in PWH with ongoing HIV viremia despite treatment with an oral ART regimen.
- Principal Investigator: Charles Mitchell
- Study Phase: TBD
- Enrollment Status: Open
-
The purpose of this study is to provide data on the PK, safety, tolerability, efficacy and acceptability of this fixed dose single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA < 50 c/mL) children 6 to less than 12 years of age, weighing at least 25 kg.All participants will switch from their pre-study ART regimen to JULUCA (50 mg DTG/25 mg RPV) administered once daily.
- Principal Investigator: Charles Mitchell
- Study Phase: TBD
- Enrollment Status: Open
-
Long-Term Clinical, Immunologic, and Virologic Profiles of Children Who Received Early Treatment for HIV
- Principal Investigator: Charles Mitchell
- Study Phase: N/A
- Enrollment Status: Closed
-
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Principal Investigator: Charles Mitchell
- Study Phase: Phase IV
- Enrollment Status: Closed
-
IMPAACT 2032 is a Phase I prospective, open-label, non-randomized opportunistic pharmacokinetic (PK) study of remdesivir in pregnant and non-pregnant women of childbearing potential for treatment of COVID-19. Women hospitalized for COVID-19 and receiving remdesivir as part of their clinical care (i.e., outside of the study) will be enrolled at study sites located in the United States. The study will describe the PK of remdesivir and its metabolite, GS-441524, and the clinical and laboratory safety outcomes through four weeks after the last administration of remdesivir and, for pregnant women, during delivery.
- Principal Investigator: Charles Mitchell
- Study Phase: Phase I
- Enrollment Status: Closed